Thesis TrackerLoading companies…
All companies
Loading…
Thesis TrackerThesis TrackerLoading…
Cogstate (ASX:CGS), a digital cognitive assessment company, is benefiting from growth in neurological drug development. In September 2026, LSN Capital Partners named Cogstate a guest pick and buy, citing its expansion beyond Alzheimer's into sleep, psychiatric and rare disease diagnostics, backed by a debt-free balance sheet. Lakehouse reported FY revenue up 15% to US$60.9 million as a more diverse mix of shorter central nervous system trials converted faster. HD Capital believes Cogstate is entering an accelerated growth phase as Alzheimer's drug development intensifies, and Ellerston highlighted its digital assessment tools. Cogstate operates in the Healthcare sector within the Health Care Technology industry, and Thesis Tracker has captured 17 comments from 6 fund managers, including LSN, Lakehouse, HD Capital and Ellerston. Founded in 1999 and headquartered in Melbourne, Cogstate provides digital cognitive tests and clinical trial services to pharmaceutical companies and healthcare providers, and partners with Eisai on clinical use.
Company figures as of 15 Oct 2026. For information only.
Fund managers including Lakehouse Capital, LSN Capital Partners, Underwood Capital, HD Capital Partners, Elston Asset Management, Ellerston Capital and Cerutty Macro Fund have invested in Cogstate Ltd (ASX:CGS).
Managers highlight expansion into new therapeutic areas, a debt-free balance sheet, faster-converting trial contracts, 15% revenue growth and accelerating Alzheimer's drug development, according to LSN, Lakehouse and HD Capital.
The available commentary is positive, though Cogstate's revenue depends on pharmaceutical clinical trial activity, which can be lumpy.
Cogstate Ltd. is a global cognitive science company headquartered in Melbourne, Australia. Founded in 1999, the firm provides digital software services to measure cognition across clinical trials, academic research, and healthcare. Its operations are divided into three segments: Clinical Trials, Healthcare, and Administration. The Clinical Trials segment provides solutions for testing drug efficacy and safety, while the Healthcare segment offers tools for detecting cognitive impairment across patient care. By specializing in cognitive assessment, Cogstate supports researchers and clinicians in monitoring brain health and measuring outcomes in clinical and medical environments.
General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.
11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.